Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Compugen ( (CGEN) ) just unveiled an update.
On May 19, 2025, Compugen Ltd. reported its first quarter 2025 financial results and provided a corporate update. The company initiated a trial for COM701 in ovarian cancer and continued its Phase 1 trial for GS-0321, licensed to Gilead. Partner AstraZeneca expanded its rilvegostomig program to ten Phase 3 trials, representing a significant potential revenue source for Compugen. The company maintains a solid financial position, with cash expected to fund operations into 2027, and announced key leadership transitions effective September 2025.
The most recent analyst rating on (CGEN) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Compugen stock, see the CGEN Stock Forecast page.
Spark’s Take on CGEN Stock
According to Spark, TipRanks’ AI Analyst, CGEN is a Neutral.
Compugen’s overall score reflects its challenging financial performance typical in biotechnology, with fluctuating revenues and profitability issues. Technical indicators show bearish trends, while valuation metrics highlight risks. The earnings call provides some optimism with strategic advancements and financial stability, but ongoing net losses and revenue declines pose challenges.
To see Spark’s full report on CGEN stock, click here.
More about Compugen
Compugen Ltd. is a clinical-stage therapeutic discovery and development company that utilizes its predictive computational discovery platform, Unigen, to identify new drug targets and biological pathways for developing cancer immunotherapies. The company has proprietary product candidates in Phase 1 development, including COM701 and COM902, for the treatment of solid tumors. Compugen is headquartered in Israel and has offices in San Francisco, CA, with shares listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.
Average Trading Volume: 276,080
Technical Sentiment Signal: Sell
Current Market Cap: $130M
For a thorough assessment of CGEN stock, go to TipRanks’ Stock Analysis page.